Table 1 Population characteristics sarcopenia-related reports
From: Drug risks associated with sarcopenia: a real-world and GWAS study
Name | Classification | Potential sarcopenia | Sarcopenia | ||
|---|---|---|---|---|---|
Frequency | Percentage | Frequency | Percentage | ||
Gender | Male | 858 | 18.0% | 22 | 66.7% |
Female | 2979 | 62.4% | 11 | 33.3% | |
Missing | 270 | 5.6% | 0 | 0.0% | |
Age | 30–45 years | 788 | 38.9% | 3 | 9.1% |
45–60 years | 1883 | 25.6% | 2 | 6.1% | |
Age over 60 | 1436 | 35.5% | 28 | 84.8% | |
Adverse outcomes | Death | 92 | 3.1% | 0 | 0.0% |
Disability | 895 | 16.2% | 2 | 6.1% | |
Hospitalization | 1107 | 49.5% | 15 | 45.5% | |
Other | 2013 | 31.2% | 16 | 48.4% | |
Reported area | North America | 3675 | 39.8% | 4 | 12.1% |
Europe | 255 | 1.1% | 10 | 30.3% | |
Asia | 47 | 0.9% | 3 | 11.1% | |
Other | 130 | 58.2% | 16 | 46.5% | |